GeneNews is Now StageZero Life SciencesOn June 19, 2019 GeneNews received shareholder approval to change the company name to StageZero Life Sciences. The new ticker symbol is now (TSX: SZLS). We are excited to embark on this exciting journey to reduce late stage cancers through early detection and bring to market our next-generation blood test for simultaneously screening for 10 cancers from a single sample of blood.
|
|
Stock Chart Press Releases SEDAR Filings Corporate Governance Shareholder Information Investor Presentation Webcast (Click link above up to view recorded webcast) |
Investor RelationsWe are StageZero Life Sciences and we are dedicated to finding cancer in the earliest stages when it is most curable. Our next-generation test, Aristotle™, is a panel for simultaneously screening for 10 cancers from a single blood sample. Aristotle has been built on the company's mRNA Sentinel Principle Technology Platform, which was used to develop one of the first commercially available blood tests for Colorectal Cancer, ColonSentry®.
Latest News |
|
Investor Relations Contacts
James R. Howard-Tripp Chairman and CEO jht@stagezerols.com Jerome Cliche Financial Communication Advisor jcliche@stagezerols.com 514-815-8799 Corporate Headquarters 30-70 East Beaver Creek Road Richmond Hill, ON L4B 3B2 905-209-2030 contact@stagezerols.com |
Stay In Touch! Subscribe to Our Investor Updates |
